The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Regular Sinus Rhythm
- 302 Downloads
This report examined the role of digitalis pharmacokinetics in helping to guide therapy with digitalis glycosides with regard to converting atrial fibrillation (AF) or flutter to regular sinus rhythm (RSR). Pharmacokinetic models of digitoxin and digoxin, containing a peripheral non-serum effect compartment, were used to analyze outcomes in a non-systematic literature review of five clinical studies, using the computed concentrations of digitoxin and digoxin in the effect compartment of these models in an analysis of their outcomes. Four cases treated by the author were similarly examined. Three literature studies showed results no different from placebo. Dosage regimens achieved ≤11 ng/g in the model’s peripheral compartment. However, two other studies achieved significant conversion to RSR. Their peripheral concentrations were 9–14 ng/g. In the four patients treated by the author, three converted using classical clinical titration with incremental doses, plus therapeutic drug monitoring and pharmacokinetic guidance from the models for maintenance dosage. They converted at peripheral concentrations of 9–18 ng/g, similar to the two studies above. No toxicity was seen. Successful maintenance was achieved, using the models and their pharmacokinetic guidance, by giving somewhat larger than average recommended dosage regimens in order to maintain peripheral concentrations present at conversion. The fourth patient did not convert, but only reached peripheral concentrations of 6–7 ng/g, similar to the studies in which conversion was no better than placebo. Pharmacokinetic analysis and guidance play a highly significant role in converting AF to RSR. To the author’s knowledge, this has not been specifically described before. In my experience, conversion of AF or flutter to RSR does not occur until peripheral concentrations of 9–18 ng/g are reached. Results in the four cases correlated well with the literature findings. More work is needed to further evaluate these provocative findings.
KeywordsAtrial Fibrillation Digoxin Atrial Flutter Digitoxin Ventricular Rate
Supported by NIH Grants EB005803 and GM068968.
Conflicts of Interest
The author has no conflicts of interest to disclose.
- 2.Jelliffe RW, Bechtol LD, Crabtree R. The bioavailability and pharmacokinetic behavior of digitoxin. Technical report 2012-1, Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine, Los Angeles, CA.Google Scholar
- 3.Jelliffe R, Milman M, Schumitzky A, Bayard D, Van Guilder M. A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage. Ther Drug Monit. [Epub 2014 Jan 31].Google Scholar
- 4.Reuning R, Sams R, Notari R. Role of pharmacokinetics in drug dosage adjustment. 1. Pharmacologic effects, kinetics, and apparent volume of distribution of digoxin. J Clin Pharmacol. 1973;13:127–41.Google Scholar
- 7.Hornestam B, Jerling M, Karlsson M, Help P, for the DAAF Trial Group. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation Trial. Eur J Clin Pharmacol. 2003;58:747–55.PubMedGoogle Scholar
- 12.Jelliffe R, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, Barbaut X, Maire P. Model-based, goal-oriented, individualized drug therapy: linkage of population modeling, new “multiple model” dosage design, Bayesian feedback, and individualized target goals. Clin Pharmacokinet. 1998;34:57–77.PubMedCrossRefGoogle Scholar
- 18.Jelliffe R, Schumitzky A, Bayard D, Leary R, Van Guilder M, Goutelle S, et al. The USC Pmetrics and Bestdose software—the software with integrated population modeling, simulation, and maximally precise dosage [software demonstration]. Population Approach Group Europe; 5–8 Jun 2012; Venice.Google Scholar
- 24.Chamberlain D. Plasma digoxin concentrations as a guide to therapeutic requirements. In: Davies D, Prichard B, editors. Biological effects of drugs in relation to their plasma concentrations. Baltimore: University Park Press; 1973. p. 135–43.Google Scholar
- 28.Jelliffe R, Bayard D, Leary R, Schumitzky A, Van Guilder M, Botnen A, et al. A hybrid Bayesian method to obtain Bayesian posterior parameter distributions in nonparametric pharmacokinetic models for individual patients. Technical Report 2011-1, Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine. http://www.lapk.org/pubsinfo/pdf/HYBRID_11-9-10.pdf.